Drug intelligence / Profile preview

Acatar

Development stage
Unknown
Lead developer
USP Zdrowie
Modality
Small Molecules
Administration
Intranasal, Oral
01

Overview

Acatar is a brand of over-the-counter (OTC) medications developed by USP Zdrowie, primarily marketed in Poland for the relief of symptoms associated with the common cold, flu, and allergic rhinitis. The brand encompasses several distinct formulations: **Acatar Control** and **Acatar Care** are nasal sprays containing the alpha-adrenergic agonist oxymetazoline hydrochloride, which provides rapid relief of nasal congestion through local vasoconstriction. **Acatar Acti-Tabs** is an oral combination of the systemic decongestant pseudoephedrine hydrochloride and the first-generation antihistamine triprolidine hydrochloride. **Acatar Zatoki** combines pseudoephedrine with the non-steroidal anti-inflammatory drug (NSAID) ibuprofen to address both congestion and sinus pain. These products are widely used for their ability to reduce nasal mucosal swelling and alleviate rhinorrhea.

Brand names
AcatarAcatar ControlAcatar Acti-TabsAcatar ZatokiAcatar CareAcatar Baby
Other names
oxymetazolinepseudoephedrine + triprolidineibuprofen + pseudoephedrine
02

Targets

ADRA1A (α1A)ADRA2A (α2A)NET (Norepinephrine Transporter)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Acatar.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acatar.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call